Compare ALTI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALTI | MNPR |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | United States |
| Employees | 490 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.2M | 368.9M |
| IPO Year | 2021 | 2019 |
| Metric | ALTI | MNPR |
|---|---|---|
| Price | $3.77 | $57.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $107.00 |
| AVG Volume (30 Days) | 143.6K | ★ 174.1K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.11 | ★ 54.99 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $254,956,000.00 | N/A |
| Revenue This Year | $18.06 | N/A |
| Revenue Next Year | $10.71 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 23.21 | N/A |
| 52 Week Low | $2.96 | $28.40 |
| 52 Week High | $5.45 | $105.00 |
| Indicator | ALTI | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 48.12 | 52.60 |
| Support Level | $3.76 | $56.15 |
| Resistance Level | $3.95 | $60.87 |
| Average True Range (ATR) | 0.21 | 3.81 |
| MACD | 0.05 | 0.40 |
| Stochastic Oscillator | 70.00 | 73.05 |
AlTi Global Inc is a wealth and investment partner to families, foundations, and institutions, helping clients activate capital, bring structure to complexity, and plan across borders and generations. The company combines the breadth of an international firm with the service offering of a family office to deliver solutions for wealth and capital. It provides services including discretionary and non-discretionary investment advisory, estate and wealth planning, trust and fiduciary, governance, philanthropy, and family office services, along with access to alternative investment opportunities. The company generates revenue from management, advisory, trustee, or administration fees, performance or incentive fees, distributions from investments, and other income or fees.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.